Youngen Biotechnology: Hotgen Biotech Establishes an AI Pharmaceutical Company to Focus on Small Nucleic Acid Drug R&D

Recently, Hotgen Biotech took a strategic step in the field of AI-enabled biomedicine by officially registering and establishing Beijing Youngen Biotechnology Co., Ltd., referred to as Youngen Biotechnology.

This marks a stage-by-stage implementation of the AI drug R&D strategy that the company launched in 2023. Relying on the technical accumulation of the X-Gen AI Drug Discovery and Design Research Center, the company will continue to increase investment in AI technology for its innovative drug business. In particular, it aims to use AI technology to reshape the R&D model for small nucleic acid drugs and accelerate the intelligent upgrade of the company's small nucleic acid drug pipeline.

As a research and development platform combining frontier algorithms and biomedicine, the X-Gen AI Drug Discovery and Design Research Center brings together interdisciplinary research talent from China and abroad in artificial intelligence, computational biology, pharmaceutical engineering, biotechnology, and related fields.

Over the past few years, the company has included AI-assisted drug design in its core R&D strategy and has accumulated a large amount of wet-lab experimental data and bioinformatics resources. At the same time, Hotgen Biotech's strategic investee, Beijing Keygen Biomed Co., Ltd., has a high-throughput experimental technology platform for small nucleic acids and several small nucleic acid drug pipelines under development. This will continue to provide training data and validation scenarios for AI model building. In return, AI-based design and prediction capabilities will guide experimental directions, forming an efficient R&D flywheel effect.

The establishment of Youngen Biotechnology will effectively integrate these high-value data assets. By building a multimodal autonomous learning framework, it aims to realize full-chain intelligence from target discovery and molecular design to clinical translation. The goal is to significantly reduce R&D costs, improve preclinical research efficiency, lay a solid foundation for future products to enter clinical development, and build a unique first-mover advantage in the AI + innovative drug R&D field.

About AI-Driven R&D for Small Nucleic Acid Drugs

Beijing Youngen Biotechnology Co., Ltd.

Beijing Youngen Biotechnology Co., Ltd. was established in June 2026 with a registered capital of RMB 20 million. It is a wholly owned subsidiary of Beijing Hotgen Biotech Co., Ltd. 

The company focuses on the full-process application of AI in the design and development of small nucleic acid drugs. It is committed to building an intelligent drug R&D platform to empower small nucleic acid drug discovery and translational medicine research, and to support the development of new quality productive forces in the biomedical industry.

Non-Inducement Statement

This press release contains forward-looking statements, which are mainly based on the current views, expectations, estimates, and predictions of the company's management. Words such as "hope," "expect," "believe," "may," "design," "effect," "evaluate," "forecast," "goal," "plan," "purpose," "will," "intend," and similar expressions related to the company are intended to indicate forward-looking statements.

Forward-looking statements are affected by risks and uncertainties. Many of these risks are difficult to predict and are usually beyond the company's control. As a result, actual results may differ from those described in the forward-looking statements. The company has no obligation to publicly update or revise any forward-looking statements.